In Eg-pt. bladder cancer is the most common type of male malignancy. ranking only after breast cancer in females in rate of incidence. The disease is characten'sed bs a predominance of locallv ads anced lesions and a high incidence of squamous cell carcinoma (Khaled. 1993) . There is a close relationship betus-een the prevalence of urinanr tract schistosomiasis and the incidence of bladder cancer. A positive history of schistosomiasis or repeated treatment of schistosomiasis with anti-bilharzial drugs are correlated With bladder cancer in 9000 of patients (Mustacchi and Shimnkin. 1958 : El-Sebai. 1961 : Al-Shukri et al.. 1987 . Different tumour markers have been evaluated for detecting Egyptian bladder cancer. With varying results in terms of sensitivitv and specificity (El-Ahmadx et al.. 1991a . 1992a . To date. tissue polypeptide antigen (TPA) has been the most reliable marker and the combined use of carcinoembryonic antigen (CEA) and ferritin with TPA has increased the diagnostic value of TPA in detecting bladder cancer (El-Ahmady. 1988 : Halim et al.. 1992 . 1993 . Urinary levels of human chorionic gonadotropin beta subunit (beta-hCG) have also been evaluated in Egyptian bladder cancer patients and patients with benign urinary tract disorders. This marker was elevated in 60.3% of cancer patients. however 29.7% of patients u ith benign disease were also elevated above the upper limit of the normal control group (Halim et al.. 1994) .
Urinar-gonadotropin peptide (UGP). also known as unnary gonadotropin fragment (UGF) and beta-core fragment. is a 10.5 kDa glycoprotein with a primarsequence identical to residues 6-40 and 55-92 of the betasubunit of human chorionic gonadotropin (hCG) (Birken et al.. 1988 (Nam et al.. 1990b ) and ovarian cancer (Cole and Nam. 1989 Recovery of known quantities of UGP spiked into urne samples ranged from 86% to 109%, with a mean of 96%. The intra-and interassay reproducibility ranged from 4.12% to 4.95% and from 6.07% to 7.85%, respectively, over the range of the assay. Pathological urine samples exhibited linear dilution response, with a mean correlation coefficient of 0.999. The assay is highly specific for UGP, exhibiting the following molar cross-reactivities: human chorionic gonadotropin (hCG, 0.11%), hCG beta-subunit (0.043%), hCG alpha-subunit (0.009%), human luteinising hormone (hLH, 0.001%), hLH beta-subunit (0.005%), human thyroidstimulating hormone and beta subunit (hTSH and hFSH beta-subunit, <0.001%) and human follicle-stimulating hormone and beta subunit (hFSH and hFSH beta-subunit, <0.001%). The assay has been optimised to eliminate crossreactivity with fragments derived from luteinising hormone that are present in urine. The following urinary analytes do not interfere with the assay at levels up to the following concentrations: urea (5 g dl-'), uric acid (150 mg dl-'), creatinine (500 mg dl-'), creatine (200 mg dl-1), vitamin C (500 mg dl-'), urobilin (4 mg dl-'), glucose (30 mg dl-') and haemoglobin (10 mg dl-'). The 4 .64 fmol ml-' for stage T Ill patients to 6.24 fmol ml-' for stage T IV patients. Median UGP values were significantly different between the stage T Ill and stage T IV patients (P = 0.05) and between the combined stage Tl and T2 patients and stage T IV patients (P=0.05) but not between the combined stage T I and T II patients and the stage T III patients. Similarly, the percentage of patients exceeding the cut-off levels increased as a function of stage. At the 0.7 fmol ml-' cut-off, 64% of stage T I and T H patients, 71% of patients with stage T III disease and 81% of stage T IV patients exceeded the cut-off. The number of patients exceeding the 1.4 fmol ml-' cut-off followed the same trend but was correspondingly lower, ranging from 57% of state T I and T II patients to 73% of stage T IV patients.
When bladder cancer patients were stratified according to grade of disease (Table HI) , mean UGP levels were lowest for grade 1 patients, and higher but similar for grade 2 and 3 patients. Grade 1 patients had a mean UGP level of 2.93 fmol ml-' and grade 2 and 3 patients had mean UGP levels of 5.67 and 4.66 fmol ml-' respectively. Median UGP levels were significantly different between grade 1 and grade 2 patients (P=0.006) but not between grade 2 and 3 patients. Overexpression of UGP values was similar for all grades at a cut-off of 0.7 fmol ml-', with 66% of grade 1 patients and 75% and 73%, respectively, of grade 2 and 3 patients exceeding the cut-off. At the higher cut off of 1.4 fmol ml-', the percentage of patients with grade 1 disease exceeding the cut-off was 44%, which was significantly lower than that for the grade 2 (66%) and grade 3 (59%) patients.
Stratification of bladder cancer patients according to nodal status and the presence of bilharzial ova in the tumour tissue is shown in Table III . For both categories, mean UGP levels in negative and positive cases were virtually identical to each other and to the mean value for all cancer patients, ranging from 4.82 to 4.88 fmol ml-'. Similarly, overexpression rates at both cut-offs were virtually identical to each other and to the value for all cancer patients, ranging from 72 -73% at the 0.7 fmol ml-' cut-off, and 58-62% at the 1.4 fmol ml-' cutoff. Finally, stratification of bladder cancer patients according to gender showed no difference in mean UGP levels (data not shown).
DiKmsion
UGP is a pan-marker and has been demonstrated to be expressed in the urine of patients with a variety of solid tumours. Most studies have focused on evaluating the utility of UGP in the management of malignant gynaecological disease, although significant elevations have been observed in other types of malignancies. This study demonstrated that UGP is also overexpressed in a majority of Egyptian patients with advanced stage bladder cancer. The source of UGP in the urine of patients with malignant disease is the metabolic breakdown of hCG species, predominantly hCG beta subunit, originating in the tumour tissue. This is corroborated by previous reports that have demonstrated the presence of hCG beta subunit in the tissues and circulation of approximately 50% of patients with bladder cancer (Oliver et al., 1988; Marcillac et al., 1992) . Other studies have shown that UGP was present in the urine of patients with hCGproducing bladder tumours (Iles et al., 1990) . Because UGP is the predominant hCG-derived species in urine, it is the most sensitive marker of hCG immunoreactivity for indicating the presence of malignancy. An additional factor contributing to the high level of UGP overexpression in this population of bladder cancer patients could be the relatively high proportion with advanced disease.
In this study population, UGP was demonstrated to be a sensitive and specific marker for malignancy. UGP (ElAbmady et al., 1992a, b; Halim et al., 1992) . However, at 100% specificity, the sensitivities of ferritin, CEA and TPA dropped markedly to 34%, 23% and 34% respectively.
The UGP cut-offs used in this study are lower than those used in other studies reported in the literature. This could be due to several factors. First, the levels of UGP in cancer patients could be expected to vary according to tumour type. Second, the populations in this study were predominantly male. Earlier studies have shown that the normal range of UGP is measurably higher in post-menopausal women compared with males and premenopausal women (Lee et al., 1991) . Finally, this study used 24 urines for UGP determination and the majority of studies reported in the literature with this marker use spot urines, usually corrected for creatinine. Because spot or early-morning spot urines are more readily obtainable than timed 24 h urines, future studies will evaluate the correlation between 24 h urines and spot urines corrected for creatinine.
Owing to its high sensitivity for detecting individuals with malignant disease at a cut-off at which no false-positives were observed in patients with benign urological disease, the clinical value of UGP could be for the differential diagnosis of these patients, particularly in high-risk populations. The application of this marker for this use needs to be evaluated in further studies.
The use of UGP is facilitated by the fact that it is a highly stable marker that is measurable in urine, which is a readily obtained and non-invasive sample. Future studies will focus on evaluating UGP expression in early stage disease, as well as for monitoring and detecting recurrent disease.
